{"id":"NCT04597632","sponsor":"Novartis Pharmaceuticals","briefTitle":"An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study","officialTitle":"A 56-week Phase IIIb/IV, Open-label, One-arm Extension Study to Assess the Efficacy and Safety of Brolucizumab 6 mg in a Treat-to-Control Regimen With Maximum Treatment Intervals up to 20 Weeks for the Treatment of Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-12-16","primaryCompletion":"2023-03-28","completion":"2023-03-28","firstPosted":"2020-10-22","resultsPosted":"2024-04-04","lastUpdate":"2024-10-09"},"enrollment":248,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Neovascular Age-related Macular Degeneration"],"interventions":[{"type":"DRUG","name":"brolucizumab","otherNames":["RTH258"]}],"arms":[{"label":"brolucizumab 6 mg","type":"EXPERIMENTAL"}],"summary":"The purpose of this extension study was to evaluate the efficacy and safety of brolucizumab used in a Treat-to-Control-regimen for treatment of patients with neovascular age-related macular degeneration who have completed the CRTH258A2303 (TALON) study. The main objective was to assess brolucizumab's potential for long durability up to 20 weeks.\n\nAll eligible participants were treated with brolucizumab regardless of their treatment in the TALON study.\n\nThe study period was 56 weeks including post-treatment follow-up.","primaryOutcome":{"measure":"Duration of the Last Interval With no Disease Activity up to Week 56 - Study Eye","timeFrame":"Up to Week 56","effectByArm":[{"arm":"Brolucizumab 6 mg","deltaMin":68,"sd":null}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":60,"countries":["United States","Australia","Belgium","Czechia","France","Germany","Israel","Italy","Malaysia","Netherlands","Portugal","South Korea","Spain","Sweden","Switzerland","Taiwan"]},"refs":{"pmids":[],"seeAlso":["https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=1913"]},"adverseEventsSummary":{"seriousAny":{"events":26,"n":248},"commonTop":["Neovascular age-related macular degeneration - Fellow eye","COVID-19","Cataract - Study eye","Nasopharyngitis","Cataract - Fellow eye"]}}